Literature DB >> 28285389

Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents.

Theodoros P Marakis1, Chrysanthi Koutsandrea2, Klio I Chatzistefanou2, Yannis Tountas3.   

Abstract

PURPOSE: To assess the psychometric properties of the Greek Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) and evaluate the factors that influence treatment satisfaction of patients with neovascular age-related macular degeneration (nAMD).
METHODS: The MacTSQ was translated into Greek and administered to 176 patients. All patients completed the SF-12 Health Survey and the Macular disease Dependent Quality of Life Questionnaire (MacDQoL) and underwent vision measurements. For test-retest reliability, a subset of 19 participants completed the MacTSQ twice, two weeks apart. Stepwise multiple linear regression analyses were performed to identify predictors of treatment satisfaction. Change in MacTSQ scores over time was assessed on 83 patients who completed the MacTSQ at a follow-up visit, one year later.
RESULTS: The intraclass correlation coefficients between the first and second test-retest administration ranged from 0.88 to 0.98 for the items and total score. Internal reliability of the total score was adequate (Cronbach's a = 0.837). Principal component analysis revealed three subscales (effectiveness, information provision and convenience, impact). The MacTSQ score showed significant correlations with SF-12 summary scales and MacDQoL scores (ρ = 0.16-0.27). The most important factor that determined the satisfaction was mental health. Distance visual acuity (VA) in better eye was the best predictor of the effectiveness subscale, and the total number of injections was a negative predictor for the convenience subscale. Treatment satisfaction increased at one-year follow-up, despite the deterioration in distance VA.
CONCLUSIONS: The Greek MacTSQ is a reliable and valid instrument for assessing nAMD patients' perceptions of treatment satisfaction, especially using its three new subscales. Treatment satisfaction is multifactorial and was primarily determined by patients' mental health status.

Entities:  

Keywords:  Age-related macular degeneration; Greece; Predictors; Psychometric properties; Treatment satisfaction questionnaire

Mesh:

Substances:

Year:  2017        PMID: 28285389     DOI: 10.1007/s10792-017-0492-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  38 in total

1.  Depression despite anti-vascular endothelial growth factor treatment of age-related macular degeneration.

Authors:  Robin Casten; Barry W Rovner; Benjamin E Leiby; William Tasman
Journal:  Arch Ophthalmol       Date:  2010-04

2.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

3.  Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.

Authors:  Jessica Boyle; Meri Vukicevic; Konstandina Koklanis; Catherine Itsiopoulos; Gwyneth Rees
Journal:  Psychol Health Med       Date:  2017-01-09       Impact factor: 2.423

4.  On the statistical reliability of letter-chart visual acuity measurements.

Authors:  A Arditi; R Cagenello
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-01       Impact factor: 4.799

5.  Beyond visual acuity: functional outcome and patient satisfaction following treatment for age-related macular degeneration.

Authors:  Sara Dubuc; Walter Wittich; Julius E Gomolin; Michael Kapusta; Olga Overbury
Journal:  Can J Ophthalmol       Date:  2009-12       Impact factor: 1.882

6.  Prevalence of age-related macular degeneration in Greece: the Thessaloniki Eye Study.

Authors:  Fotis Topouzis; Anne L Coleman; Alon Harris; Eleftherios Anastasopoulos; Fei Yu; Archimidis Koskosas; Theofanis Pappas; Leonidas Mavroudis; M Roy Wilson
Journal:  Am J Ophthalmol       Date:  2006-09-05       Impact factor: 5.258

7.  Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life.

Authors:  Katharina M Droege; Philipp S Muether; Manuel M Hermann; Albert Caramoy; Ulrike Viebahn; Bernd Kirchhof; Sascha Fauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-20       Impact factor: 3.117

Review 8.  Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010.

Authors:  Rupert R A Bourne; Jost B Jonas; Seth R Flaxman; Jill Keeffe; Janet Leasher; Kovin Naidoo; Maurizio B Parodi; Konrad Pesudovs; Holly Price; Richard A White; Tien Y Wong; Serge Resnikoff; Hugh R Taylor
Journal:  Br J Ophthalmol       Date:  2014-03-24       Impact factor: 4.638

9.  +Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life.

Authors:  Jan Mitchell; James S Wolffsohn; Alison Woodcock; Stephen J Anderson; Carolyn V McMillan; Timothy Ffytche; Martin Rubinstein; Winfried Amoaku; Clare Bradley
Journal:  Health Qual Life Outcomes       Date:  2005-04-14       Impact factor: 3.186

10.  Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life.

Authors:  Maiko Inoue; Akira Arakawa; Shin Yamane; Kazuaki Kadonosono
Journal:  Clin Ophthalmol       Date:  2014-09-04
View more
  2 in total

1.  Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration.

Authors:  Paola S Calles-Monar; María R Sanabria; Ana M Alonso-Tarancon; Rosa M Coco-Martin; Agustín Mayo-Iscar
Journal:  Drugs Aging       Date:  2022-04-29       Impact factor: 3.923

2.  nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey.

Authors:  Anke Schmid; Felicitas Bucher; Erika Liczenczias; Sara Maslanka Figueroa; Bettina Müller; Hansjürgen Agostini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-05-13       Impact factor: 3.535

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.